stoxline Quote Chart Rank Option Currency Glossary
  
Evoke Pharma, Inc. (EVOK)
0.6206  0.016 (2.5%)    03-28 10:19
Open: 0.5901
High: 0.64
Volume: 6,956
  
Pre. Close: 0.605
Low: 0.5901
Market Cap: 5(M)
Technical analysis
2024-03-28 9:45:39 AM
Short term     
Mid term     
Targets 6-month :  0.79 1-year :  0.88
Resists First :  0.68 Second :  0.75
Pivot price 0.62
Supports First :  0.56 Second :  0.46
MAs MA(5) :  0.59 MA(20) :  0.63
MA(100) :  0.91 MA(250) :  1.29
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  16.6 D(3) :  16.7
RSI RSI(14): 38.2
52-week High :  2.42 Low :  0.55
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ EVOK ] has closed above bottom band by 21.8%. Bollinger Bands are 34.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.61 - 0.61 0.61 - 0.62
Low: 0.55 - 0.56 0.56 - 0.56
Close: 0.6 - 0.61 0.61 - 0.61
Company Description

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Headline News

Tue, 26 Mar 2024
Investors Who Bought Evoke Pharma (NASDAQ:EVOK) Shares Five Years Ago Are Now Down 92% - Yahoo Movies Canada

Mon, 25 Mar 2024
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com - Defense World

Thu, 21 Mar 2024
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer - Yahoo Finance

Sat, 16 Mar 2024
Evoke Pharma Full Year 2023 Earnings: EPS Misses Expectations - Simply Wall St

Fri, 15 Mar 2024
Evoke Pharma Down 2.16% To $0.66 After Earnings Miss - InvestorsObserver

Fri, 15 Mar 2024
Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript - Yahoo Finance Australia

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 0 (M)
Shares Float 8 (M)
Held by Insiders 5.03e+006 (%)
Held by Institutions 9.6 (%)
Shares Short 408 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin -150.5 %
Operating Margin -112.7 %
Return on Assets (ttm) -49.1 %
Return on Equity (ttm) -1 %
Qtrly Rev. Growth 5.18e+006 %
Gross Profit (p.s.) 552.5
Sales Per Share 177.19
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio 0
PEG Ratio -0.1
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.16
Stock Dividends
Dividend 0
Forward Dividend 59230
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android